Valo Health to Participate in Piper Sandler and Goldman Sachs Investor Conferences

BOSTON, Nov. 8, 2021 /​PRNewswire/​— Valo Health, LLC (“Valo”), the tech­nol­o­gy com­pa­ny using human-cen­tric data and arti­fi­cial intel­li­gence (AI) pow­ered com­pu­ta­tion to trans­form the drug dis­cov­ery and devel­op­ment process, announced today that its CEO and founder, David Berry, will present at the fol­low­ing investor con­fer­ences in Novem­ber and December:

EVENT: Piper San­dler 33rd Annu­al Vir­tu­al Health­care Con­fer­ence
WHAT: A pre-record­ed ses­sion with David Berry will be avail­able for atten­dees
DATE: Novem­ber 29, 2021

EVENT: Gold­man Sachs Inau­gur­al Investor Con­fer­ence — Byte-olo­gy: The Con­ver­gence of Biotech­nol­o­gy with Tech­nol­o­gy
WHAT: David Berry will join lead­ers from Recur­sion, Relay Ther­a­peu­tics, Exsci­en­tia and Schro­ding­er in the Biotech­nol­o­gy Pan­el
DATE: Decem­ber 9, 2021 10:00 am EST

About Valo Health

Valo Health, LLC (“Valo”) is a tech­nol­o­gy com­pa­ny built to trans­form the drug dis­cov­ery and devel­op­ment process using human-cen­tric data and arti­fi­cial intel­li­­gence-dri­ven com­pu­ta­tion. As a dig­i­tal­ly native com­pa­ny, Valo aims to ful­ly inte­grate human-cen­tric data across the entire drug devel­op­ment life cycle into a sin­gle uni­fied archi­tec­ture, there­by accel­er­at­ing the dis­cov­ery and devel­op­ment of life-chang­ing drugs while simul­ta­ne­ous­ly reduc­ing costs, time, and fail­ure rates. The com­pa­ny’s Opal Com­pu­ta­tion­al Plat­form™ is an inte­grat­ed set of capa­bil­i­ties designed to trans­form data into valu­able insights that may accel­er­ate dis­cov­er­ies and enable Valo to advance a robust pipeline of pro­grams across car­dio­vas­cu­lar meta­bol­ic renal, oncol­o­gy, and neu­rode­gen­er­a­tive dis­ease. Found­ed by Flag­ship Pio­neer­ing and head­quar­tered in Boston, MA, Valo also has offices in Lex­ing­ton, MA, San Fran­cis­co, CA, Prince­ton, NJ, and Bran­ford, CT. To learn more, vis­it www​.val​o​health​.com

Con­tacts:
Investors: Graeme Bell, Chief Finan­cial Offi­cer
267−326−2129
gbell@​valohealth.​com

Media: Jen­nifer Han­ley, VP Cor­po­rate Com­mu­ni­ca­tions
jhanley@​valohealth.​com